Subsequent works have shown that blocking the effect of S100A9, S100A8 or S100A8/A9 in various ways in a tumor setting, can reduce immune suppression and tumor growth and affect the accumulation of myeloid cell populations (Table 1). Here, IGKV1D-22 is linked to neoplasm.